Targets › BRD3
5 programs from 5 companies in 20 trials: 15 Phase 1, 3 Phase 3, 2 Phase 2; Oncology, Other, Infectious disease; next expected readout Nov 2026.
Chromatin reader that recognizes and binds acetylated histones, thereby controlling gene expression and remodeling chromatin structures. Recruits transcription factors and coactivators to target gene sites, and activates RNA polymerase II machinery for transcriptional elongation. (UniProt, Q15059)
Open in Phaseline: the race on BRD3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Pelabresib Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 3 | Hematologic Malignancy; Myelofibrosis; Primary Myelofibrosis (PMF); Healthy Participants … | Nov 2026 |
| National Cancer Institute (NCI) | ZEN003694 (ZEN-3694) BET bromodomain inhibitor | BRD2, BRD3, BRD4 | Phase 2 | Advanced Malignant Solid Neoplasm; Metastatic Colorectal Adenocarcinoma; Anatomic Stage III Breast Cancer AJCC v8; Advanced NUT Carcinoma … | Dec 2026 |
| Resverlogix | Apabetalone (RVX000222) Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 2 | Post-Acute COVID-19 Syndrome | – |
| Chia Tai Tianqing Pharmaceutical Group | TQB3617 Capsules Bromodomain and Extra-Terminal (BET) inhibitor | BRD2, BRD3, BRD4, BRDT | Phase 1 | Myelofibrosis | Dec 2026 |
| Bristol-Myers Squibb | Ezobresib (BMS-986158) Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 1 | Multiple Myeloma; Myelofibrosis | Aug 2028 |
Myelofibrosis (3) Advanced Malignant Solid Neoplasm (3) Primary Myelofibrosis (PMF) (2) Anatomic Stage III Breast Cancer AJCC v8 (2) Hematologic Malignancy (1) Healthy Participants (1) Advanced Malignancies (1) Advanced Malignancies and Hepatic Impairment (1) Metastatic Colorectal Adenocarcinoma (1) Advanced NUT Carcinoma (1) Recurrent Endometrial Carcinoma (1) Metastatic Colorectal Carcinoma (1)
small molecule (5)
Novartis (1) Chia Tai Tianqing Pharmaceutical Group (1) National Cancer Institute (NCI) (1) Bristol-Myers Squibb (1) Resverlogix (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.